Skip to main content
SpringerLink
Log in

Current Adjuvant Therapeutic Approaches for Pancreatic Cancer

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Pancreatic cancer continues to be the fourth leading cause of death despite advancements in surgical and adjuvant therapeutic approaches. In the present review, the current cytotoxic therapeutic approaches and advanced targeted therapies are objectively discussed with consideration to the current literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47(1):5–27.

    Article  CAS  PubMed  Google Scholar 

  2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  3. Gaedcke J, Gunawan B, Grade M, et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg. 2010;395(4):451–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Balcom JH, Castillo CF. Can we predict resectability in pancreatic cancer? Ann Gastroenterol. 2000;13(3):201–6.

    Google Scholar 

  5. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57.

    Article  CAS  PubMed  Google Scholar 

  6. Hackert T, Buchler M, Werner J. Current state of the surgical management of pancreatic cancer. Cancers. 2011;3:1253–73.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. Erratum in: Arch Surg 1986 Sep;121(9):1045.

  8. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.

    Article  CAS  PubMed  Google Scholar 

  9. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  10. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.

    Article  CAS  PubMed  Google Scholar 

  12. Maeda A, Boku N, Fukutomi A, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol. 2008;38(3):227–9.

    Article  PubMed  Google Scholar 

  13. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18(3):335–48.

    Article  CAS  PubMed  Google Scholar 

  14. Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP. 2013;14(2):112–8.

    PubMed  Google Scholar 

  15. Uesaka K, Fukutomi A, Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30. 2012;(suppl 34; abstr 145).

  16. Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31. 2013;(suppl; abstr 4008).

  17. Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99(2):108–13.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang Y, Satoh K, Li M. Novel therapeutic modalities and drug delivery in pancreatic cancer – an ongoing search for improved efficacy. Drugs Context. 2012;2012:212244. doi:10.7573/dic.212244

    PubMed Central  PubMed  Google Scholar 

  19. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80(10):751–5.

    Article  Google Scholar 

  20. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3(3):373–8.

    CAS  PubMed  Google Scholar 

  21. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–9.

    Article  CAS  PubMed  Google Scholar 

  22. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.

    CAS  PubMed  Google Scholar 

  24. Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007;8(16):2719–27.

    Article  CAS  PubMed  Google Scholar 

  25. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  26. Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Yu X, Zhang Y, Chen C, Yao Q, Li M. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2010;1805(1):97–104.

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Berlanga-Acosta J, Gavilondo-Cowley J, Barco-Herrera DG, Martin-Machado J, Guillen-Nieto G. Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinog Mutagen. 2011;2:1.

    Article  Google Scholar 

  29. Einama T, Ueda S, Tsuda H, et al. Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Exp Ther Med. 2012;3(6):931–6.

    PubMed Central  PubMed  Google Scholar 

  30. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol. 2003;194(1):13–9.

    Article  CAS  PubMed  Google Scholar 

  31. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000;6(3):747–53.

    CAS  PubMed  Google Scholar 

  32. Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol. 2004;54(Suppl 1):S69–77.

    PubMed  Google Scholar 

  33. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand–receptor interactions. FEBS Lett. 1997;410(1):83–6.

    Article  CAS  PubMed  Google Scholar 

  34. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203–12.

    Article  CAS  PubMed  Google Scholar 

  35. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998;18(6B):4613–9.

    CAS  PubMed  Google Scholar 

  36. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13(3):565–9.

    CAS  PubMed  Google Scholar 

  37. Mu DQ, Peng YS, Xu QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol. 2004;10(4):471–5.

    CAS  PubMed  Google Scholar 

  38. Zhu H, Liang ZY, Ren XY, Liu TH. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Cancer Biol Ther. 2006;5(12):1693–8.

    Article  CAS  PubMed  Google Scholar 

  39. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549–54.

    Article  CAS  PubMed  Google Scholar 

  40. Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(3):318–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Peace DJ, Chen W, Nelson H, Cheever MA. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol. 1991;146(6):2059–65.

    CAS  PubMed  Google Scholar 

  42. Shin SH, Kim SC, Hong SM, et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013;42(2):216–22.

    Article  CAS  PubMed  Google Scholar 

  43. Sirivatanauksorn V, Sirivatanauksorn Y, Lemoine NR. Molecular pattern of ductal pancreatic cancer. Langenbecks Arch Surg. 1998;383(2):105–15.

    Article  CAS  PubMed  Google Scholar 

  44. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266–76.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA. 2009;106(11):4254–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425(6960):851–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas. 2011;40(4):557–66.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861–8.

    Article  PubMed  Google Scholar 

  50. Mahadevan D, Von Hoff DD. Tumor–stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6(4):1186–97.

    Article  CAS  PubMed  Google Scholar 

  51. Le A, Rajeshkumar NV, Maitra A, Dang CV. Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res. 2012;18(16):4285–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Yang ZY, Yuan JQ, Di MY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8(3):e57528.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Li J, Saif MW. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29–June 2, 2009. JOP. 2009;10(4):361–5.

    PubMed  Google Scholar 

  54. Squadroni M, Fazio N. Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 2010;14(4):386–94.

    CAS  PubMed  Google Scholar 

  55. Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41(1):189–209.

    Article  PubMed  Google Scholar 

  56. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.

    Article  CAS  PubMed  Google Scholar 

  57. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231–7.

    Article  PubMed  Google Scholar 

  58. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.

    Article  CAS  PubMed  Google Scholar 

  59. Stathopoulos GP, Trafalis D, Athanasiou A, Bardi G, Chandrinou H. Serious hematologic complications following erlotinib treatment. Anticancer Res. 2010;30(3):973–6.

    CAS  PubMed  Google Scholar 

  60. Faloppi L, Andrikou K, Cascinu S. Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther. 2013;13(5):791–801.

    Article  CAS  PubMed  Google Scholar 

  61. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6(5):1936–48.

    CAS  PubMed  Google Scholar 

  62. Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP. 2007;8(1):4–15.

    PubMed  Google Scholar 

  63. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22(13):2610–6.

    Article  CAS  PubMed  Google Scholar 

  64. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008;9(1):39–44.

    Article  CAS  PubMed  Google Scholar 

  65. Kullmann F, Hollerbach S, Dollinger MM, et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer. 2009;100(7):1032–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007;18(10):1652–9.

    Article  CAS  PubMed  Google Scholar 

  67. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  68. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4(1):121–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74.

    Article  CAS  PubMed  Google Scholar 

  70. Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19(31):5051–60.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21(6):1152–62.

    Article  CAS  PubMed  Google Scholar 

  72. Ko AH, Youssoufian H, Gurtler J, et al. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012;30(4):1597–606.

    Article  CAS  PubMed  Google Scholar 

  73. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Long Y, Sun Q, Wu J, Wang Y, Jiao S. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: a case report. Oncol Lett. 2014;7(5):1594–8.

    PubMed Central  PubMed  Google Scholar 

  76. Qiu Y, Yun MM, Xu MB, Wang YZ, Yun S. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol. 2013;18(4):657–65.

    Article  CAS  PubMed  Google Scholar 

  77. Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology. 2013;2(12):e26662.

    Google Scholar 

  78. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955–64.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195–205.

    Article  CAS  PubMed  Google Scholar 

  80. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90(8):3539–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel- L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17:94–100.

    Article  PubMed  Google Scholar 

  82. Gujar SA, Lee PW. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol. 2014;4:77.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Nakao A, Kasuya H, Sahin TT, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011;18(3):167–75.

    Article  CAS  PubMed  Google Scholar 

  84. Ishizaki H, Manuel ER, Song GY, et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2011;60(1):99–109.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest

Fusun Ozmen, Tevfik Tolga Şahin, and M. Mahir Ozmen declare no conflict of interest.

Compliance with ethics guidelines

This review is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Basic Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey

    Fusun Ozmen

  2. Department of Surgery, Medical School, Hacettepe University, Ankara, Turkey

    Tevfik Tolga Şahin & M. Mahir Ozmen

Authors
  1. Fusun Ozmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tevfik Tolga Şahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Mahir Ozmen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Mahir Ozmen.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 191 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozmen, F., Şahin, T.T. & Ozmen, M.M. Current Adjuvant Therapeutic Approaches for Pancreatic Cancer. Adv Ther 32, 42–56 (2015). https://doi.org/10.1007/s12325-015-0177-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-015-0177-5

Keywords

Search

Navigation